N@N

CYCC, CXM, CUR, CRTX, CRA, CLSN, Biomed - Genetics Stocks 61.41% undervalued

^{Published on 2011-01-26 12:33:35 - WOPRAI}
 

January 26, 2011 / M2 PRESSWIRE / BUYINS.NET / http://www.squeezetrigger.com is monitoring the Biomed - Genetics sector and these stocks are the most undervalued as of today. CYCLACEL PHARMACEUTICALS INC (NASDAQ:CYCC), CARDIUM THERAPEUTICS INC (AMEX:CXM), NEURALSTEM INC (AMEX:CUR), CORNERSTONE THERAPEUTICS INC (NASDAQ:CRTX), CELERA CORP (NASDAQ:CRA), CELSION CORP (NASDAQ:CLSN) are all expected to go Up as they are undervalued according to industry standard valuation metrics. The valuation model employs a three-factor approach to stock valuation using fundamental variables--the company's trailing 12-month Earnings-Per-Share (EPS), the analyst consensus estimate of the company's forecasted 12-month EPS, and the 30-year Treasury yield--to create a highly accurate reflection of a company's fair value.

The chart below displays the projected Fair Value and Valuation discount/premium of the most undervalued stocks in the highlighted industry group:

     Symbol     Company Name                        Last Close     Fair Value     Valuation                   Industry               
     CYCC       CYCLACEL PHARMACEUTICALS INC        1.51           3.91           61.41% undervalued          Biomed - Genetics      
     CXM        CARDIUM THERAPEUTICS INC            0.388          1.21           67.87% undervalued          Biomed - Genetics      
     CUR        NEURALSTEM INC                      1.97           1.99           1.20% undervalued           Biomed - Genetics      
     CRTX       CORNERSTONE THERAPEUTICS INC        5.86           9.86           40.59% undervalued          Biomed - Genetics      
     CRA        CELERA CORP                         6.28           10.61          40.79% undervalued          Biomed - Genetics      
     CLSN       CELSION CORP                        2.62           3.39           22.66% undervalued          Biomed - Genetics      

Here are some of the variables that are utilized when calculating the Fair Market Valuation of a stock: Long-run EPS growth rate, Duration of Business-growth-cycle, Volatility of EPS growth rate, Systematic or beta risk of the firm, Correlation between the firm's EPS and the interest rate environment, EPS growth volatility, Dividend payout ratio, Buffer earnings, Interest rate related criteria: Interest rate (30 year yield) long-run level, Duration of interest rate cycle, Interest rate volatility. The Fair Market Valuation uses 12-month historic and forecasted EPS values and the current 30-year treasury yield as primary determinants. When calculating risk/return values such as the Sharpe ratio, the historic periods used are five years.

Some expected results of the Valuation Model are: the valuation of a stock increases in a declining interest rate environment. Increasing current and/or projected EPS will produce a higher Valuation. While long-term EPS growth would produce a corresponding long-term Valuation increase, concomitant long-term interest rate increases would offset EPS growth and depress the Valuation. The shorter a company's own business cycle, the higher its stock Valuation will be.

CYCLACEL PHARMACEUTICALS INC (NASDAQ:CYCC) - Cyclacel Pharmaceuticals, Inc., a development stage biopharmaceutical company, engages in the discovery, development, and commercialization of mechanism-targeted drugs to treat human cancer and other serious disorders. Its orally-available drugs in clinical development include Sapacitabine (CYC682), an oral nucleoside analogue, which is in phase II studies for the treatment of hematological malignancies, such as acute myeloid leukemia in the elderly, myelodysplastic syndromes, cutaneous T-cell lymphoma, and lung cancer; Seliciclib (CYC202), a CDK (cyclin dependent kinase) inhibitor, which is in phase II studies for the treatment of lung cancer and nasopharyngeal cancer; and CYC116, an Aurora kinase and VEGFR2 inhibitor that is in phase I studies for patients with advanced solid tumors. The company, through its subsidiary, ALIGN Pharmaceuticals, LLC, markets directly Xclair Cream for radiation dermatitis, as well as Numoisyn Liquid and Numoisyn Lozenges for xerostomia in the United States. It focuses on building a diversified biopharmaceutical business focused in hematology, oncology, and other therapeutic areas based on a portfolio of commercial products and a development pipeline of novel drug candidates. The company was founded in 1992 and is headquartered in Berkeley Heights, New Jersey.

CARDIUM THERAPEUTICS INC (AMEX:CXM) - Cardium Therapeutics, Inc. focuses on the acquisition and development of biomedical product opportunities and businesses that have the potential to address unmet medical needs, and definable pathways to partnering, commercialization, and other monetizations. Its investment portfolio includes the Tissue Repair Company and Cardium Biologics, which are medical technology companies primarily focused on the development of therapeutic products for wound healing, bone repair, and cardiovascular indications. Its product candidates include Generx, a DNA-based angiogenic growth factor therapeutic that is in phase 3 clinical trail for the treatment of patients with advanced coronary artery disease; Excellarate, a tissue repairs product candidate that is in Phase 2b clinical trial for the treatment of non-healing, neuropathic diabetic foot ulcers; and Excellagen, which is completed Phase 2b clinical trial for the treatment of chronically non-healing diabetic foot ulcers. The company was founded in 2003 and is headquartered in San Diego, California.

NEURALSTEM INC (AMEX:CUR) - Neuralstem, Inc., a biopharmaceuticals company, focuses on the development and commercialization of treatments for central nervous system diseases based on transplanting human neural stem cells and small molecule drugs. It uses its proprietary human neural stem cell technology as a tool for use in the small-molecule drug discovery, as well as to create cell therapy biotherapeutics for the treatment of central nervous system diseases, various neurodegenerative conditions, and for the regenerative repair of acute diseases. The company was founded in 1996 and is headquartered in Rockville, Maryland.

CORNERSTONE THERAPEUTICS INC (NASDAQ:CRTX) - Cornerstone Therapeutics Inc., a specialty pharmaceutical company, engages in the acquisition, development, and commercialization of branded and generic pharmaceuticals for the respiratory and related markets primarily in the United States. It offers a line of products, including CUROSURF, an natural lung surfactant, for the treatment of respiratory distress syndrome in premature infants; FACTIVE, a fluoroquinolone with an activity against certain microorganisms implicated in respiratory infections, such as multi-drug resistant strains of Streptococcus pneumoniae; SPECTRACEF, a cephalosporin for the treatment of respiratory and skin infections; and ZYFLO CR, a leukotriene synthesis inhibitor, for prophylaxis and chronic treatment of asthma. The company also markets ALLERX dose pack products that are prescribed for the treatment of symptoms of allergic rhinitis; and HYOMAX family of products, which may be prescribed for functional intestinal disorders to reduce symptoms such as those seen in mild dysenteries, diverticulitis and irritable bowel syndrome. In addition, it develops cough/cold product candidates comprising CRTX 067, CRTX 069, CRTX 072, and CRTX 074; allergy product candidates consisting of CRTX 058 and CRTX 070; CRTX 073, an anti-asthma product candidate; and anti-infective product candidates, including CRTX 062 and CRTX 068. The company is headquartered in Cary, North Carolina. As of December 31, 2009, Cornerstone Therapeutics Inc. operates as a subsidiary of Chiesi Farmaceutici S.p.A.

CELERA CORP (NASDAQ:CRA) - Celera Corporation offers personalized disease management through a combination of products and services primarily in the United States. The companys Lab Services segment provides a portfolio of clinical laboratory tests and disease management services designed to help physicians improve cardiovascular disease treatment regimens for their patients. This segment offers clinical laboratory testing services that characterize and monitor cardiovascular disease risks; and personalized and ongoing therapeutic compliance education. It also provides principal tests, including LDL-S3GGE test that measures low-density lipoprotein (LDL) size as a subclass distribution divided in seven regions and characterizes the amount of LDL distributed in these regions; HDL-S10GGE test that measures high-density lipoprotein (HDL) size as a subclass distribution divided across five HDL regions and characterizes the amount of HDL distributed in these regions; Kinesin-Like Protein 6 (KIF6) test, which detects a variant in a gene called KIF6; and LPA genotype test to detect a variant of the LPA gene known as 4399Met. Its Products segment develops and manufactures molecular diagnostic products for disease detection, prediction of disease predisposition, monitoring of disease progression and disease severity, and determination of patient responsiveness to treatments. Celera Corporation has a strategic alliance with Abbott Laboratories to discover, develop, and commercialize molecular diagnostic products for disease detection, prediction of disease predisposition, disease progression monitoring, and therapy selection. The companys Corporate segment licenses small molecule drug development programs and Life Technologies intellectual property to third parties for use in the diagnostic field; and establishes collaborations to develop cancer therapies based on its proteomics discoveries. Celera Corporation was founded in 1998 and is headquartered in Alameda, California.

CELSION CORP (NASDAQ:CLSN) - Celsion Corporation, an oncology drug development company, develops and commercializes targeted chemotherapeutic oncology drugs based on its proprietary heat-activated liposomal technology. The company is developing its lead product, ThermoDox that is in Phase III clinical trial for primary liver cancer; and in phase II clinical trial for treatment of recurrent chest wall breast cancer. It has a license agreement with Yakult Honsha to commercialize and market ThermoDox for the Japanese market. The company also has a license agreement with Duke University under which it received exclusive rights to commercialize and use Duke's thermo-liposome technology. In addition, Celsion Corporation has a joint research agreement with Royal Phillips Electronics to evaluate the combination of Phillips' high intensity focused ultrasound with its ThermoDox to determine the potential of this combination to treat a range of cancers. The company was founded in 1982 and is based in Columbia, Maryland.

About BUYINS.NET

BUYINS.NET, www.buyins.net , monitors trading in all US stocks in real time and maintains massive databases of short sale and naked short sale time and sales data, short squeeze SqueezeTrigger prices, market maker price movements, shareholder data, statistical data on earnings, sector correlation, seasonality, hedge fund trading strategies, comparable valuations. Reports include:

REGULATORY & COMPLIANCE NEWS

Friction Factor -- market maker surveillance system tracking Level II market makers in all stocks to determine Price Friction and compliance with new "Fair Market Making Requirements"

RegSHO Naked Shorts -- tracks EVERY failure to deliver in all US stocks and tracks all Threshold Security Lists daily for which stocks have naked shorts that are not in compliance with Regulation SHO

INVESTMENTS & TRADING

SqueezeTrigger -- 29 billion cell database tracks EVERY short sale (not just total short interest) in all US stocks and calculates volume weighted price that a short squeeze will begin in each stock.

Earnings Edge -- predicts probability, price move and length of move before and after all US stock earnings reports.

Seasonality -- predicts probability, price move and length of move based on exact time of year for all US stocks.

Group Trader -- tracks sector rotation and stock correlation to its sector and predicts future moves in ALL sectors and industry groups.

Pattern Scan -- automates tracking of every technical pattern and predicts time and size of move in all stocks.

GATS (Global Automated Trading System) -- tracks all known trading strategies and qualifies and quantifies which are working best in real time.

DISCLAIMER:

BUYINS.NET is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. BUYINS.NET has not been compensated by any of the above mentioned companies. Past performance is not indicative of future results. Please visit our web site, www.buyins.net , for complete risks and disclosures.

Contact:

BUYINS.NET Thomas Ronk 800-715-9999 tom@buyins.net www.buyins.net